Skip to main content

Zimmer Biomet Holdings(ZBH-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low90.92
Day High94.15
Open:93.01
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Zimmer Biomet Holdings

Select a category then submit the form to load news
Tipranks
Stifel Nicolaus Remains a Buy on Zimmer Biomet Holdings (ZBH)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Taysha Gene Therapies (TSHA) and Zimmer Biomet Holdings (ZBH)
Tipranks
Zimmer Biomet’s New Knee Implant Study Builds a Quiet Catalyst for Long-Term Growth
Tipranks
BTIG Sticks to Its Buy Rating for Zimmer Biomet Holdings (ZBH)
Tipranks
Zimmer Biomet’s New Stemless Shoulder Study Signals Strategic Push in Joint Reconstruction
StockStory
3 Reasons to Avoid ZBH and 1 Stock to Buy Instead
ZBH
StockStory
3 Reasons to Avoid ZBH and 1 Stock to Buy Instead
ZBH
StockStory
The Top 5 Analyst Questions From Zimmer Biomet’s Q4 Earnings Call
ZBH
Tipranks
Barclays Sticks to Their Sell Rating for Zimmer Biomet Holdings (ZBH)
MarketBeat
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH
MarketBeat.com
Tipranks
RBC Capital Remains a Buy on Zimmer Biomet Holdings (ZBH)
Tipranks
Zimmer Biomet Holdings (ZBH) Receives a Hold from Canaccord Genuity
Tipranks
Wells Fargo Keeps Their Hold Rating on Zimmer Biomet Holdings (ZBH)
Tipranks
Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Incyte (INCY) and Zimmer Biomet Holdings (ZBH)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Exelixis (EXEL), Edwards Lifesciences (EW) and Zimmer Biomet Holdings (ZBH)
Tipranks
Zimmer Biomet Earnings Call Balances Growth and Risk
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zimmer Biomet Holdings (ZBH) and OrganiGram Holdings (OGI)
StockStory
ZBH Q4 Deep Dive: U.S. Salesforce Overhaul Drives Guidance Caution Amid Product Momentum
ZBH
Motley Fool
Zimmer Biomet (ZBH) Q4 2025 Earnings Transcript
StockStory
Zimmer Biomet (NYSE:ZBH) Beats Q4 CY2025 Sales Expectations
ZBH
StockStory
What To Expect From Zimmer Biomet’s (ZBH) Q4 Earnings
ZBH
Zacks Investment Research
Can Intuitive Surgical Sustain Robust Top-line Growth in 2026?
Can Intuitive Surgical Sustain Robust Top-line Growth in 2026?
Tipranks
Morgan Stanley Remains a Hold on Zimmer Biomet Holdings (ZBH)
StockStory
3 Reasons ZBH is Risky and 1 Stock to Buy Instead
ZBH
Tipranks
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Roche Holding AG (OtherRHHVF) and Zimmer Biomet Holdings (ZBH)
StockStory
3 Value Stocks with Open Questions
ARCO
Tipranks
Analysts Offer Insights on Healthcare Companies: Rein Therapeutics (RNTX), Zimmer Biomet Holdings (ZBH) and Theravance Biopharma (TBPH)
StockStory
Q3 Rundown: Zimmer Biomet (NYSE:ZBH) Vs Other Surgical Equipment & Consumables - Diversified Stocks
ZBH
StockStory
3 Cash-Producing Stocks with Open Questions
MQ
StockStory
1 Profitable Stock to Research Further and 2 Facing Challenges
AIR
Tipranks
Zimmer Biomet Holdings (ZBH) Gets a Hold from Bernstein
Tipranks
Goldman Sachs downgrades Zimmer Biomet Holdings (ZBH) to a Sell

Profile

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.